title: Adjunctive pharmacologic therapy in percutaneous coronary intervention: part II anticoagulant therapy.
abstract: Pharmacological adjuvant therapies to protect against procedure-related thrombotic complication are indispensable during percutaneous coronary intervention. In addition to antiplatelet therapy, use of anticoagulants to prevent acute thrombotic complication during percutaneous coronary intervention is essential. Besides unfractionated heparin (UFH), new anticoagulants have been developed and compared with UFH. Low-molecular weight heparins, direct thrombin inhibitors (e.g. bivalirudin), and recently developed agents such as fondaparinux (a factor Xa inhibitor) provide new alternatives to conventional UFH.
authors.affiliation: Department of Cardiology, College of Medicine, Kyung Hee University Medical Center, Seoul, Korea.
authors.forename: Soo-Joong
authors.initials: SJ
authors.lastname: Kim
authors.forename: Robert P
authors.initials: RP
authors.lastname: Giugliano
authors.forename: Ik-Kyung
authors.initials: IK
authors.lastname: Jang
mesh_terms: D015906:Angioplasty, Balloon, Coronary / Q000009:adverse effects; D000925:Anticoagulants / Q000009:adverse effects / Q000627:therapeutic use*; D003327:Coronary Disease / Q000628:therapy*; D005343:Fibrinolytic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D006470:Hemorrhage / Q000139:chemically induced; D006801:Humans; D013927:Thrombosis / Q000097:blood / Q000209:etiology / Q000517:prevention & control*; D016896:Treatment Outcome
chemical_list: D000925:Anticoagulants; D005343:Fibrinolytic Agents